Craft

Insulet

Stock Price

$169.7

2023-09-15

Market Capitalization

$12.2 B

2023-09-14

Revenue

$1.3 B

FY, 2022

Insulet Summary

Company Summary

Overview
Insulet Corporation, a medical device company, develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The Company offers Omnipod Insulin Management System (Omnipod System), which consists of the OmniPod, an easy-to-use continuous insulin delivery system and Personal Diabetes Manager, a handheld wireless device. It also customizes the Omnipod System technology platform for the delivery of subcutaneous drugs across various therapeutic areas. Insulet Corporation sells and markets its Omnipod System through a combination of direct sales representatives and independent distributors.
Type
Public
Status
Active
Founded
2000
HQ
Acton, MA, US | view all locations
Website
https://www.insulet.com
Cybersecurity rating
ESG rating
50-59 out of 100|View all ESG data
Sectors

Key People

  • Shacey Petrovic

    Shacey Petrovic, Director, President, Chief Executive Officer

  • Charles Alpuche

    Charles Alpuche, Executive Vice President, Chief Operating Officer

    • Jim Hollingshead

      Jim Hollingshead, Director

      • Bret Christensen

        Bret Christensen, Chief Commercial Officer

      Operating MetricsView all

      Patents Issued

      23

      FY, 2016

      Patents Pending

      32

      FY, 2016

      LocationsView all

      14 locations detected

      • Acton, MA HQ

        United States

        100 Nagog Park

      • Billerica, MA

        United States

        600 Technology Park Dr

      • Irvine, CA

        United States

        1562 Reynolds Ave

      • Nashville, TN

        United States

        3102 West End Ave #400

      • Salt Lake City, UT

        United States

        155 N 400 W #300

      • San Diego, CA

        United States

        9276 Scranton Rd #4th

      and 8 others

      Insulet Financials

      Summary Financials

      Revenue (Q2, 2023)
      $396.5M
      Gross profit (Q2, 2023)
      $264.9M
      Net income (Q2, 2023)
      $27.3M
      Cash (Q2, 2023)
      $660.1M
      EBIT (Q2, 2023)
      $31.1M
      Enterprise value
      $12.9B

      Footer menu